Pros | - | ![]() 5Y returns in the top 25% of the category. ![]() Among most bought funds within the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 4/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 6 Years | ||
Fund Size | 219 Cr | 2912 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹100 | ||
Expense Ratio | 0.47% | 0.85% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 33 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.72%) Divi's Laboratories Ltd (6.23%) Lupin Ltd (5.83%) Max Healthcare Institute Ltd Ordinary Shares (5.34%) Apollo Hospitals Enterprise Ltd (5.31%) | Cohance Lifesciences Ltd (9.72%) Sun Pharmaceuticals Industries Ltd (9.66%) Cipla Ltd (9.53%) Ipca Laboratories Ltd (8.16%) Globus Medical Inc Class A (5.63%) | ||
No of Sectors | 3 | 2 | ||
Top 3 Sectors | Health (95.67%) Basic Materials (3.32%) Industrial (1.01%) | Health (98.44%) Financial Services (1.56%) | ||
Equity % | 97.48% | 99.87% | ||
Debt % | - | - | ||
P/E | 40.75 | 39.97 | ||
P/B | 6.43 | 5.1 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.19% | -1.09% | ||
3-Month Return | 6.48% | -0.33% | ||
6-Month Return | -3.54% | -8.69% | ||
1-Year Return | 19.46% | 13.71% | ||
3-Year Return | 23.47% | 24.08% | ||
5-Year Return | - | 25.37% |
Sharpe | 0.87 | 0.9 | ||
Alpha | 2.45 | 2.05 | ||
Beta | 0.9 | 0.86 | ||
Standard Deviation | 16.38 | 15.94 | ||
Information Ratio | 0.36 | 0.07 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Chirag Dagli |